Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
03 March 2021 - 12:50AM
InvestorsHub NewsWire
Ayala Pharmaceuticals
to
Participate
in
Upcoming
Virtual
Investor Conferences
REHOVOT, Israel
& WILMINGTON, Del. - InvestorsHub NewsWire
-- March
2,
2021
-
Ayala
Pharmaceuticals,
Inc. (NASDAQ: AYLA), a clinical-stage
oncology company focused on developing and commercializing small
molecule therapeutics for patients suffering from rare and
aggressive cancers, today
announced that
Ayala
management will present
at
three
upcoming
virtual
investor
conferences:
-
H.C.
Wainwright & Co. Global Life
Sciences Investor Conference:
Available for
on-demand viewing starting Tuesday,
March
9, 2021
at
7:00
am
ET.
-
Oppenheimer &
Co. 31st
Annual
Healthcare Conference: Corporate
Presentation on Tuesday, March 16,
2021 at 11:20 am ET.
-
33rd
Annual
Roth Capital
Partners Conference:
Fireside Chat
on
Wednesday, March
17,
2021
at
9:30
am ET.
A live
webcast of each
event
may be
accessed by visiting the Events &
Presentations section of Ayala's
website at
ir.ayalapharma.com.
An
archived replay of
each
webcast
will be available on the website for
approximately
90 days
following the presentations.
About
Ayala Pharmaceuticals
Ayala
Pharmaceuticals, Inc. is a clinical-stage oncology company focused
on developing and commercializing small molecule therapeutics for
patients suffering from rare and aggressive cancers. Ayala's
approach is focused on predicating, identifying and addressing
tumorigenic drivers of cancer through a combination of its
bioinformatics platform and next-generation sequencing to deliver
targeted therapies to underserved patient populations. The company
has two product candidates under development, AL101 and AL102,
targeting the aberrant activation of the Notch pathway with gamma
secretase inhibitors to treat a variety of tumors including Adenoid
Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell
Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple
Myeloma (MM) (in collaboration with Novartis). AL101 has received
Fast Track Designation and Orphan Drug Designation from the U.S.
FDA and is currently in a Phase 2 clinical trial for patients with
ACC (ACCURACY)
bearing Notch activating mutations and in a Phase 2 clinical trial
for patients with TNBC (TENACITY)
bearing Notch activating mutations and other gene rearrangements.
AL102 is currently being advanced to a Phase 2/3 clinical trials
for patients with desmoid tumors (RINGSIDE). For more information,
visit www.ayalapharma.com.
Contacts:
Investors:
Julie
Seidel
Stern Investor
Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com
Ayala
Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From Apr 2024 to May 2024
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Ayala Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Ayala Pharmaceuticals Inc News Articles